151 related articles for article (PubMed ID: 23492822)
1. Predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance.
Dietel M; Jöhrens K; Laffert M; Hummel M; Bläker H; Müller BM; Lehmann A; Denkert C; Heppner FL; Koch A; Sers C; Anagnostopoulos I
Cancer Gene Ther; 2013 Apr; 20(4):211-21. PubMed ID: 23492822
[TBL] [Abstract][Full Text] [Related]
2. Molecular Pathology: A Requirement for Precision Medicine in Cancer.
Dietel M
Oncol Res Treat; 2016; 39(12):804-810. PubMed ID: 27889782
[TBL] [Abstract][Full Text] [Related]
3. A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance.
Dietel M; Jöhrens K; Laffert MV; Hummel M; Bläker H; Pfitzner BM; Lehmann A; Denkert C; Darb-Esfahani S; Lenze D; Heppner FL; Koch A; Sers C; Klauschen F; Anagnostopoulos I
Cancer Gene Ther; 2015 Sep; 22(9):417-30. PubMed ID: 26358176
[TBL] [Abstract][Full Text] [Related]
4. Molecular diagnostics and personalized medicine in oncology: challenges and opportunities.
Normanno N; Rachiglio AM; Roma C; Fenizia F; Esposito C; Pasquale R; La Porta ML; Iannaccone A; Micheli F; Santangelo M; Bergantino F; Costantini S; De Luca A
J Cell Biochem; 2013 Mar; 114(3):514-24. PubMed ID: 22991232
[TBL] [Abstract][Full Text] [Related]
5. Human tissue in systems medicine.
Caie PD; Schuur K; Oniscu A; Mullen P; Reynolds PA; Harrison DJ
FEBS J; 2013 Dec; 280(23):5949-56. PubMed ID: 24118991
[TBL] [Abstract][Full Text] [Related]
6. Changing pathology with changing drugs: tumors of the gastrointestinal tract.
Cervera P; Fléjou JF
Pathobiology; 2011; 78(2):76-89. PubMed ID: 21677471
[TBL] [Abstract][Full Text] [Related]
7. [Response predictive biomarkers to targeted therapies in oncology].
Harlé A; Merlin JL
Ann Biol Clin (Paris); 2013 Nov; 71():89-97. PubMed ID: 24235332
[TBL] [Abstract][Full Text] [Related]
8. Personalized oncology: recent advances and future challenges.
Kalia M
Metabolism; 2013 Jan; 62 Suppl 1():S11-4. PubMed ID: 22999010
[TBL] [Abstract][Full Text] [Related]
9. Personalized medicine and development of targeted therapies: The upcoming challenge for diagnostic molecular pathology. A review.
Dietel M; Sers C
Virchows Arch; 2006 Jun; 448(6):744-55. PubMed ID: 16736190
[TBL] [Abstract][Full Text] [Related]
10. The role of molecular diagnostics in cancer diagnosis and treatment.
Ozretić L; Heukamp LC; Odenthal M; Buettner R
Onkologie; 2012; 35 Suppl 1():8-12. PubMed ID: 22286582
[TBL] [Abstract][Full Text] [Related]
11. Digital pathology in personalized cancer therapy.
Słodkowska J; García-Rojo M
Stud Health Technol Inform; 2012; 179():143-54. PubMed ID: 22925795
[TBL] [Abstract][Full Text] [Related]
12. Tissue sampling in lung cancer: a review in light of the MERIT experience.
Reck M; Hermes A; Tan EH; Felip E; Klughammer B; Baselga J
Lung Cancer; 2011 Oct; 74(1):1-6. PubMed ID: 21658788
[TBL] [Abstract][Full Text] [Related]
13. Competitive allele specific TaqMan PCR for KRAS, BRAF and EGFR mutation detection in clinical formalin fixed paraffin embedded samples.
Didelot A; Le Corre D; Luscan A; Cazes A; Pallier K; Emile JF; Laurent-Puig P; Blons H
Exp Mol Pathol; 2012 Jun; 92(3):275-80. PubMed ID: 22426079
[TBL] [Abstract][Full Text] [Related]
14. Detection of Chromosomal Abnormalities with Different In Situ Hybridisation Techniques--the Usefulness in the Qualification of Cancer Patients for Molecularly-Targeted Therapies.
Nicoś M; Wojas-Krawczyk K; Krawczyk P; Milanowski J
Adv Clin Exp Med; 2015; 24(4):715-23. PubMed ID: 26469118
[TBL] [Abstract][Full Text] [Related]
15. [Possibilities and limitations of stratified medicine based on biomarkers and targeted therapies in oncology].
Ludwig WD
Z Evid Fortbild Qual Gesundhwes; 2012; 106(1):11-22. PubMed ID: 22325103
[TBL] [Abstract][Full Text] [Related]
16. High-resolution melting analysis as a sensitive prescreening diagnostic tool to detect KRAS , BRAF , PIK3CA , and AKT1 mutations in formalin-fixed, paraffin-embedded tissues.
Ney JT; Froehner S; Roesler A; Buettner R; Merkelbach-Bruse S
Arch Pathol Lab Med; 2012 Sep; 136(9):983-92. PubMed ID: 22938585
[TBL] [Abstract][Full Text] [Related]
17. Targeted therapies of solid cancers: new options, new challenges.
Awada A; Aftimos PG
Curr Opin Oncol; 2013 May; 25(3):296-304. PubMed ID: 23493191
[TBL] [Abstract][Full Text] [Related]
18. Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody.
Capper D; Preusser M; Habel A; Sahm F; Ackermann U; Schindler G; Pusch S; Mechtersheimer G; Zentgraf H; von Deimling A
Acta Neuropathol; 2011 Jul; 122(1):11-9. PubMed ID: 21638088
[TBL] [Abstract][Full Text] [Related]
19. Individualized targeted therapy for glioblastoma: fact or fiction?
Weller M; Stupp R; Hegi M; Wick W
Cancer J; 2012; 18(1):40-4. PubMed ID: 22290256
[TBL] [Abstract][Full Text] [Related]
20. Hotspot oncomutations: implications for personalized cancer treatment.
Myers MB; Wang Y; McKim KL; Parsons BL
Expert Rev Mol Diagn; 2012 Jul; 12(6):603-20. PubMed ID: 22845481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
